Alterity Therapeutics (ATHE) Other Operating Expenses (2016 - 2024)
Alterity Therapeutics' (ATHE) quarterly Other Operating Expenses came in at -$89582.9 in Q4 2024, down 1910.08% year-on-year from $4949.1 in Q1 2024, and down 1910.08% quarter-over-quarter from -$4456.7 in Q4 2023.
Alterity Therapeutics (ATHE) Other Operating Expenses (2016 - 2024) Analysis & Trends
Alterity Therapeutics' Other Operating Expenses history runs 6 years deep, the most recent figure standing at -$89582.9 for Q4 2024.
- On a quarterly basis, Other Operating Expenses fell 1910.08% year-over-year to -$89582.9 in Q4 2024; TTM through Dec 2025 was -$89582.9, a 4.74% increase from a year earlier, with the FY2025 full-year figure at -$42980.1, down 124.97% from the prior year.
- Other Operating Expenses fell to -$89582.9 in Q4 2024 per ATHE's latest filing, from -$4456.7 in the prior quarter.
- Across five years, Other Operating Expenses topped out at -$4456.7 in Q4 2023 and bottomed at -$89582.9 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alterity Therapeutics | 29.68 Bn | 29.68 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -89,582.90 |
| Dec 31, 2023 | -4,456.68 |
| Dec 31, 2019 | 87,328.62 |
| Dec 31, 2018 | 142,967.80 |
| Dec 31, 2017 | -469,835.65 |
| Dec 31, 2016 | -372,092.82 |